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Abstract
Respiratory syncytial virus (RSV) infection of HeLa cells induces fusion, but transient expression of the three viral glycoproteins induces
fusion poorly, if at all. We found that neuraminidase treatment of RSV-infected cells to remove sialic acid (SA) increases fusion dramatically
and that the same treatment of transiently transfected cells expressing the three viral glycoproteins, or even cells expressing the fusion (F)
protein alone, results in easily detectable fusion. Neuraminidase treatment of the effector cells, expressing the viral glycoproteins, enhanced
fusion while treatment of the target cells did not. Likewise, infectivity was increased by treating virions with neuraminidase, but not by
treating target cells. Reduction of charge repulsion by removal of the negatively charged SA is unlikely to explain this effect, since removal
of negative charges from either membrane would reduce charge repulsion. Infection with neuraminidase-treated virus remained heparan-
sulfate-dependent, indicating that a novel attachment mechanism is not revealed by SA removal. Interestingly, neuraminidase enhancement
of RSV infectivity was less pronounced in a virus expressing both the G and the F glycoproteins, compared to virus expressing only the
F glycoprotein, possibly suggesting that the G protein sterically hinders access of the neuraminidase to its fusion-enhancing target.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Respiratory syncytial virus (RSV) is a member of the
Pneumovirinae subfamily of the Paramyxoviridae family of
negative strand RNA viruses (Collins et al., 2001). Many of
the members of the other subfamily, Paramyxovirinae, have
a hemagglutinin-neuraminidase (HN) attachment protein
which binds sialic acid (SA) on the surface of target cells
(Lamb and Kolakofsky, 2001). Upon binding to SA, the HN
protein is thought to undergo a conformation change and in
some way communicate this change to the fusion (F) pro-
tein, which then acts to fuse the viral membrane with the
target cell membrane. During infection, the neuraminidase
function of HN removes SA from cellular glycoproteins and
glycolipids, so that the virions produced will not bind to the
producer cell or to each other, thereby enhancing their
infectivity.
Instead of an HN attachment protein, RSV expresses its
glycoprotein (G), which is heavily decorated with O-linked
carbohydrate chains and in this way resembles a mucin
(Collins, 1990). The G protein binds glycosaminoglycans,
most importantly heparan sulfate (HS), on the surface of
target cells to initiate infection (Feldman et al., 1999; Hallak
et al., 2000a; Krusat and Streckert, 1997). The RSV F
protein is capable of mediating infectivity without the G or
small hydrophobic (SH) glycoproteins (Karron et al., 1997).
In fact, after a virion binds to a target cell, the F protein is
capable of efficiently mediating infection and fusion on its
own, without any signal from the G protein (Techaar-
pornkul et al., 2001).
The mature, cleaved F protein bears three N-linked gly-
cosyl chains (Zimmer et al., 2001), while the G protein is
heavily glycosylated, with 3% of its molecular mass being
contributed by N-linked and 55% by O-linked chains (Lam-
bert, 1988). Both types of carbohydrate chains frequently
terminate with SA, linked to galactose or N-acetylgalac-
tosamine residues.
We have observed that neuraminidase treatment greatly
enhances syncytium formation in RSV-infected cells and in
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cells expressing the F protein from a cytoplasmic plasmid.
Lambert (Lambert, 1988) reported that neuraminidase treat-
ment of RSV increases infectivity by 50%. However, since
the neuraminidase was not removed from the virus prepa-
ration before cells were inoculated, it was not clear whether
the treatment of the virus or the cells or both was respon-
sible for this effect. Another report indicated that this effect
was due to increased binding of neuraminidase-treated virus
to target cells (Walter A, 1993).
The removal of SA from the surface of HIV-infected
cells has also been shown to enhance syncytium formation
(Sun et al., 2001). Neuraminidase treatment of HIV virions
has been shown to increase their infectivity (Hu et al.,
1996). The increase in infection correlated with increased
binding of virions and the removal of charge repulsion was
proposed as the mechanism of the enhancement in both of
these studies.
We have used a two-population cell–cell fusion assay
and a viral infectivity assay to examine the effect of neur-
aminidase treatment on “effector” cells and virions, and on
“target” cells, separately. Our results show that the neur-
aminidase acts on the effector cell or virus rather than on the
target cell. Since the G and F glycoproteins are the only
viral proteins involved in RSV attachment and entry
(Techaarpornkul et al., 2001), we compared RSV express-
ing both proteins with RSV expressing only the F protein.
Neuraminidase treatment had a greater effect on the virus
expressing the F protein alone, indicating that its fusion-
enhancing effect is not on the G protein.
Results
Neuraminidase treatment of infected cells increases
syncytium formation
HeLa cells infected with rgRSV–SGF, a recombinant
RSV expressing green fluorescent protein (GFP) and all
three viral glycoproteins, produce few syncytia by 24 h
postinfection (Fig. 1A). Neuraminidase treatment of these
infected cells results in the formation of large syncytia
(Fig. 1B).
A similar effect was observed in HeLa cells transiently
expressing the F protein and GFP. GFP expression allows
visualization of transfected cells and the syncytia that they
form. Very little fusion was observed in these cells 48 h
posttransfection (Fig. 1C). After neuraminidase treatment,
syncytia were easily detectable (Fig. 1D). Cotransfection of
the G protein (Fig. 1E) or the G and SH protein (Fig. 1G)
genes along with that of the F protein did not noticeably
enhance syncytia formation following neuraminidase treat-
ment (Fig. 1F and H, respectively). Similar results were
observed in BHK cells and HEp-2 cells (data not shown).
We found that transient expression of the F protein alone
induced obvious fusion, comparable to that induced by F in
the presence of G or G and SH. This is contrary to an earlier
report (Heminway et al., 1994), where neuraminidase was
not used, but expression of all three glycoproteins was
found to induce much greater fusion than the expression of
the F protein alone.
Neuraminidase treatment of the effector or target cells
SA, the terminal sugar residue on most N- and O-linked
oligosaccharides, is responsible for much of the negative
charge on cell surfaces. On neighboring cells, these negative
charges might provide a repulsive force that would work
against fusion with a virus-infected cell. The enhanced fu-
sion following neuraminidase treatment might then be due
to removal of this repulsive force. If so, removal of SA from
either the effector (those expressing the viral F protein) or
the target cell would decrease this repulsion and increase
fusion.
We examined this possibility in a quantitative two-pop-
ulation fusion assay (Nussbaum et al., 1994; Techaar-
pornkul et al., 2001). In this assay, the effector, RSV-
infected cells were also infected with recombinant vaccinia
vT7lacOI expressing T7 polymerase. The target population
was infected with another recombinant vaccinia virus,
vCB21RlacZ (Alkhatib et al., 1996), carrying a -galacto-
sidase gene under the control of the T7 polymerase pro-
moter. Fusion between cells of the two populations would
allow the T7 polymerase from the effector cell population to
drive expression of -galactosidase, whose enzymatic ac-
tivity is then measured by a colorimetric assay. Since we
have previously demonstrated that the SH protein does not
enhance fusion (Techaarpornkul et al., 2001), we compared
the effect of neuraminidase treatment of cells infected with
rgRSV–GF, which expresses the G and F proteins as its only
glycoproteins and rgRSV–F, which expresses the F protein
as its only glycoprotein.
Neuraminidase treatment of the rgRSV–GF-infected ef-
fector cells caused a fourfold increase in fusion activity
(Fig. 2A). However, neuraminidase treatment of the target
cell population did not enhance fusion. In fact, it had a
minor inhibitory effect. Treatment of both populations en-
hanced fusion also, but not as much as treatment of the
effector cells alone. Therefore, removal of SA specifically
from the effector cells causes an increase in fusion effi-
ciency.
To examine the role played by the G protein in fusion
enhancement by neuraminidase, we tested rgRSV–F-in-
fected effector cells in the same assay. Neuraminidase treat-
ment of the effector cells enhanced fusion sixfold, but neur-
aminidase treatment of the target cells did not (Fig. 2B).
Neuraminidase treatment of both cell populations also en-
hanced fusion, but not to the extent that treatment of the
effector cells alone did. Fusion enhancement was similar for
cells expressing the F protein, whether or not they expressed
the G protein, suggesting that the target of the neuramini-
dase is not the G protein.
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Fig. 1. The effect of neuraminidase treatment on fusion of HeLa cells expressing RSV glycoproteins. Cells in A and B were infected with rgRSV. Cells in
C through H were transfected with pTM1–GFP and inoculated with vaccinia vTF7, expressing the T7 polymerase, alone (I and J). In addition, the cells in
other panels were transfected with: (C and D) pTM1–F; (E and F) pTM1–F and pTM1–G; (G and H) pTM1–F, pTM1–G, and pTM1–SH. Panels on the right
were treated with 200 mU/ml neuraminidase for 1 h at 37°C, while those on the left were mock treated. Cells were viewed under an inverted fluorescence
microscope and photographed with a digital camera. Results are representative of six separate experiments.
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Neuraminidase treatment of virions or target cells
To determine whether neuraminidase has the same effect
on virus infectivity as on cell–cell fusion, we diluted stocks
of rgRSV–GF and rgRSV–F in serum-free medium and
treated them with neuraminidase at 37°C for 1 h. The virus
was further diluted in serum-containing medium to mini-
mize the possible effects of the neuraminidase on the target
cells. Neuraminidase treatment of virus increased the infec-
tivity of rgRSV–GF by a maximum of 60% compared to
untreated virus (Fig. 3A). This enhancement of infectivity is
similar to that seen previously with wild-type RSV express-
ing all three viral glycoproteins (Lambert, 1988). The effect
of neuraminidase on rgRSV–F infectivity was more dra-
matic, causing more than a 400% increase in infection at the
highest neuraminidase concentration tested. The effect of
neuraminidase treatment of both viruses was dose depen-
dent. Similar results were obtained with Vero and HeLa
cells (data not shown).
As in the cell–cell fusion assay described above, we
treated the target cells with neuraminidase before incuba-
tion, in this case to determine whether the removal of SA
from the target cells enhanced infectivity. No appreciable
increase in the number of infected cells was observed (Fig.
3B). This result is consistent with that of the cell–cell fusion
experiments and confirms that the presence or absence of
SA on the surface of target cells has no effect on fusion, in
this case resulting in infection. Similar results were obtained
for neuraminidase-treated Vero and HeLa cells (data not
shown).
Comparison of the effects of neuraminidase and
spinoculation on infectivity
Spinoculation probably increases the efficiency of infec-
tion by bringing the virus in closer contact with target cells,
Fig. 3. The effect on infectivity of treating virus or target cells with
neuraminidase. (A) rgRSV–GF or rgRSV–F was treated with a series of
neuraminidase concentrations for 1 h at 37°C. The virus was then diluted
in medium and used to inoculate HEp-2 cells. (B) HEp-2 cells were treated
with a series of neuraminidase concentrations for 1 h at 37°C. The neur-
aminidase was removed and the cells were washed three times before virus
inoculation. After incubation at 37°C for 20 h, the number of infected cells
per field was counted, using the 10 objective of an inverted fluorescence
microscope. In A, the number of infected cells is represented as a fold
increase in infection, which was calculated as the ratio of the number of
cells infected after neuraminidase treatment to the number of cells infected
after mock neuraminidase treatment. Results show mean values of three
samples and are representative of three separate experiments.
Fig. 2. The effect of neuraminidase treatment on cells in a two-population
fusion assay. HeLa “effector” cells were inoculated with rgRSV–GF (A) or
rgRSV–F (B), and 18 h later with a recombinant vaccinia virus, vT7lacOI,
encoding T7 polymerase. To account for background from non-fusion-
related events, control cells were infected with vT7lacOI alone. A second,
“target” population was inoculated with recombinant vaccinia virus,
vCB21RlacZ, carrying a -galactosidase gene driven by a T7 promoter.
Forty-eight hours pi with RSV, either the effector (E) or the target (T) cell
population or both were treated with 70 mU/ml neuraminidase for 1 h at
37°C. The target population was removed from the surface using 0.5 mM
EDTA and resuspended in OptiMEM, 2% FBS. This population was then
overlaid on the effector population and incubated for 3 h at 37°C. The cells
were lysed and -galactosidase was assayed by the colorimetric CRPG
assay. Background signal ( 0.04 in each case) due to non-fusion-related
events was subtracted from each reading. Results show mean values of
three samples and are representative of five separate experiments.
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perhaps overcoming the repulsive forces between cell and
virus. If neuraminidase were to overcome repulsive forces
by removing the SA charge, then the effects of these two
procedures on infection should be similar. To test this pos-
sibility, rgRSV–GF and rgRSV–F viruses were treated with
neuraminidase or mock treated before inoculation. After
virus addition, one of the plates was centrifuged while the
other was not.
After an 18-h incubation at 37°C, the number of infected
(green) cells was quantified by flow cytometry (Fig. 4). In
the absence of neuraminidase, spinoculation increased in-
fectivity of both viruses by approximately 400%. The in-
fectivity of rgRSV–GF treated with neuraminidase and spi-
noculated was similar to that of untreated, spinoculated
virus. However, neuraminidase treatment of the virus en-
hanced rgRSV–F infection following spinoculation by an
additional 50%. As shown above, neuraminidase treatment
has a greater effect on rgRSV–F infection than on
rgRSV–GF infection. Particularly in the case of rgRSV–F,
neuraminidase treatment had an additive effect on spinocu-
lation, suggesting that their modes of action differ.
The role of glycosaminoglycans in neuraminidase-
mediated enhancement of infectivity
To initiate infection of cultured cell lines such as HEp2,
RSV binds glycosaminoglycans, particularly HS, on the cell
surface. Removal of SA by neuraminidase might enable the
virus to use a novel pathway of entry. To examine this
possibility, we treated target cells with heparinase I and then
inoculated them with virus which had been treated with
neuraminidase or not. The treatment of target cells with
heparinase I greatly reduced infection (Fig. 5), consistent
with previous results (Hallak et al., 2000a). Treatment of
both viruses with neuraminidase enhanced infection, similar
to other results presented here. However, neuraminidase
treatment did not compensate for the loss of infectivity
caused by the removal of HS from the cell surface. This
result clearly indicates that neuraminidase-treated virions
still require HS for efficient entry. Therefore, neuraminidase
treatment does not appear to allow infection via a novel
receptor.
Exposed galactose residues in enhancement of infection
SA residues are linked by 2–3 or 2–6 glycosidic
bonds to subterminal galactose or N-acetylgalactosamine
residues on oligosaccharide chains. When SA is removed by
neuraminidase treatment, these residues are exposed. Per-
Fig. 4. The effect of neuraminidase treatment and spinoculation on infectivity. rgRSV–GF or rgRSV–F was treated with 70 mU/ml neuraminidase or mock
treated and used to inoculate cells in two parallel plates. One plate was spun at 1700g for 15 min at 4°C, while the other was not. After incubation at 37°C
for 20 h, the number of infected cells was counted by flow cytometry. The number of infected cells is represented as a fold increase in infection, which was
calculated as the ratio of the number of cells infected after treatment (with neuraminidase or spinoculation or both) to the number of cells infected after mock
neuraminidase treatment. Results are representative of three independent experiments.
Fig. 5. The effect of heparinase I treatment of cells prior to inoculation with
neuraminidase-treated rgRSV–GF or rgRSV–F. Virus was treated with 70
mU/ml neuraminidase for 1 h at 37°C or mock treated. HEp2 cells were
treated with 2 mIU/ml heparinase I for 2 h at 18°C. The heparinase was
removed and the cells were washed and inoculated with virus. After
incubation at 37°C for 20 h, the number of infected cells in a 10 field
were counted. Six random fields were counted in each case.
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haps it is these newly revealed carbohydrates on the viral
surface that enable the virus to bind to receptors for these
sugars on the target cell surface. To test this possibility, we
treated rgRSV–GF and rgRSV–F with neuraminidase and
then inoculated cells in the presence of increasing amounts
of D-galactose or N-acetylgalactosamine (Fig. 6) which
should compete for binding to galactose or galactosamine
receptors. In the case of desialylyated HIV gp120, these
sugars compete for binding to the galactose receptors on
human dendritic cells and monocytes at a concentration of
10 mM (Manca, 1992). In our experiments, neither of these
sugars decreased the infectivity of neuraminidase-treated
virus or untreated virus at concentrations of up to 40 mM.
Therefore, the exposure of the subterminal galactose or
N-acetylgalactosamine residues does not seem to be in-
volved in the enhanced infection after neuraminidase treat-
ment of the viruses. Similar results were obtained with
multivalent BSA–lactosyl and BSA–N-acetylgalactosamide
complexes (data not shown).
Effect of neuraminidase treatment on virus binding
Neuraminidase enhancement of fusion and infection
could be due to an enhancement of either binding or fusion.
To test the effect of neuraminidase treatment on virion
binding, we metabolically labeled both rgRSV–GF and
rgRSV–F virions with [35S]methionine and cysteine, puri-
fied them twice over linear sucrose gradients, and used them
in a binding assay, as previously described (Techaarpornkul
et al., 2001). As observed before, rgRSV–GF virions bind
cells much more effectively than rgRSV–F virions (Fig.
7A), due to the presence of the G protein, which is princi-
pally responsible for binding to heparan sulfate on cells
(Techaarpornkul et al., 2001, 2002).
Purified virions were treated with neuraminidase and
their binding to target cells was compared to that of mock-
treated virions (Fig. 7A). rgRSV–GF virions bound 10% (P
 0.08, analysis of variance, ANOVA) more efficiently,
and rgRSV–F virions bound 50% (P  0.003, ANOVA)
more efficiently when treated with neuraminidase. How-
ever, this enhanced binding can account for only a portion
of the enhanced infectivity (Fig. 7B). The binding of
rgRSV–GF increased by 10%, while its infectivity in-
creased by 70%. Similarly, the binding of rgRSV–F in-
creased by 50%, while its infectivity increased by 140%.
These results suggest that in addition to binding, neuramin-
idase treatment also enhances a postbinding step, possibly
fusion.
Fig. 6. The effect of soluble galactose and N-acetylgalactosamine on the infectivity of rgRSV–GF (A, C) or rgRSV–F (B, D) after neuraminidase (NA) or
mock treatment. Virion infectivity was assayed following inoculation in the presence of increasing concentrations of galactose (A and B) or N-
acetylgalactosamine (C and D). Eight fields were counted in each case.
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Effect of neuraminidase on the state of virion aggregation
Neuraminidase treatment could increase infectivity if it
were to disaggregate viral particles. If virions disaggregate,
the particle size would decrease and consequently their
migration in a sucrose velocity gradient would also de-
crease. To test this possibility, we used 35S-metabolically
labelled rgRSV–GF and rgRSV–F, which had been purified
twice by sucrose density gradient. Purified virions were
treated with neuraminidase or mock treated and layered on
top of a 15–45% linear sucrose gradient and centrifuged at
15,000g for 10 min. Fractions were collected and the cpm in
each fraction were determined in a beta-counter (Fig. 8).
Neuraminidase-treated virus separated in a pattern similar to
that of mock-treated virus, indicating that neuraminidase
treatment did not disaggregate virions.
Discussion
RSV infection of cultured cells results in fusion, gener-
ating multinucleated syncytia. This cell–cell fusion process
is similar to the virus–cell fusion that initiates infection and
is, as such, an important tool for assessing F protein func-
tion. In this report we show that neuraminidase treatment of
RSV-infected cells dramatically increases fusion. Neur-
aminidase treatment was previously shown to increase the
infectivity of HIV-1 (Hu et al., 1996) and to increase syn-
cytium formation in cultures of cells infected with HIV-1
(Sun et al., 2001). The most likely explanation appeared to
be the removal of repulsive negative charges from either
surface since neuraminidase treatment of either the effector
or the target surface increased infectivity. In our experi-
ments on RSV-induced fusion, removal of SA from the
effector, but not the target surface, enhanced fusion. In fact,
removal of SA from the target cells actually had a negative
effect on cell–cell fusion. The cause of this negative effect
is not clear. Likewise, spinoculation, which likely over-
comes charge repulsion by centrifugal force, greatly en-
hanced virus infection, but did not supplant the neuramini-
dase effect. These results suggest that the neuraminidase
effect is not due to a general removal of charge repulsion
between effector and target surfaces.
Another possible explanation is that exposure of the
penultimate sugar residue, galactose or N-acetylgalac-
tosamine, on the effector membrane allows binding to a
galectin receptor on target cells. We do not specifically
know whether the cells used in this study express galectin
receptors, but one such molecule, the asialoglycoprotein
receptor, is expressed at a high level on the hepatoma cell
line, HepG2 (Ashwell and Morell, 1974). However, we
found that neuraminidase treatment of RSV increased in-
Fig. 8. The effect of neuraminidase treatment on velocity sedimentation of
rgRSV–GF and rgRSV–F. 35S-labeled virus twice-purified through a su-
crose gradient was mock treated or treated with 70 mU/ml neuraminidase
for 1 h at 37°C and then layered on top of a 15–45% linear sucrose
gradient. After centrifugation at 15,000g for 10 min, fractions were col-
lected from the bottom of the tube, and cpm were determined in a beta-
counter.
Fig. 7. The effect of neuraminidase treatment on binding of rgRSV–GF and
rgRSV–F to cells. 35S-labeled virus, twice-purified through a sucrose
gradient, was mock treated or treated with 60 mU/ml neuraminidase for 1 h
at 37°C and then incubated with confluent monolayers of HeLa cells
(20,000 cpm/well) for 1 h at 4°C. Unbound virus was removed by washing
four times with cold medium. (A) To assess binding, the cells were lysed
in RIPA buffer and bound radioactivity was counted using a beta-counter.
Difference in the neuraminidase-treated and untreated rgRSV–F virions (P
 0.05 as determined by an analysis of variance (ANOVA) test). By the
same test, the increase in rgRSV–GF virion binding was not significant (P
 0.08). (B) To assess infectivity, growth medium was added and after
incubation at 37°C for 20 h the number of infected cells per field was
counted, using the 10 objective of an inverted fluorescence microscope.
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fectivity to similar levels for both HEp2 and HepG2 cells
(N. Barretto and M. Peeples, unpublished data), suggesting
that galectin binding is not involved in the enhancement of
fusion and infection. This result concurs with the failure of
soluble galactose and N-acetylgalactosamine to block infec-
tion. Furthermore, neuraminidase-treated virus remained
dependent on HS for infectivity, indicating that an addi-
tional HS-independent attachment mechanism is not in-
volved. Neuraminidase treatment slightly increased the
binding of rgRSV–GF and rgRSV–F virions to target cells,
but this was not sufficient to account for the increase in
infection, indicating that neuraminidase also enhances a
step other than binding.
Neuraminidase treatment of both rgRSV–GF- and
rgRSV–F-infected cells greatly enhanced their ability to
fuse with neighboring cells, indicating that the G protein is
not the important target for the fusion-enhancing effect of
the neuraminidase. Neuraminidase treatment of rgRSV–F
virions had a similar enhancing effect but, surprisingly, the
same treatment of rgRSV–GF virions had a much less
dramatic effect. These findings suggest that the glycoprotein
packing in the virions may decrease the access of the neur-
aminidase to the critical SA residue(s) on the G or F protein.
Of course, we cannot rule out the possibility that these
critical SA residues are on other host-derived glycoproteins
and glycolipids on the virion surface. Removal of SA from
host-derived molecules may serve to decrease steric hin-
drance between the viral and the cellular membranes in-
volved in the fusion event.
The three N-glycosyl chains on the mature F protein
have been shown to modulate its fusion activity (Zimmer et
al., 2001). Mutations that remove them individually affect
fusion without affecting cell-surface expression of the F
protein (Zimmer et al., 2001). Removal of the N70 chain on
F2 caused a 40% increase in fusion. Perhaps removal of just
the terminal SA on this chain would also result in more
efficient fusion. Removal of the N500 carbohydrate chain
on the F1 subunit completely destroyed fusion activity. This
chain lies within the HR2 (helical repeat 2) region, which is
involved in the formation of the 6-helix bundle (Lawless-
Delmedico et al., 2000; Zhao et al., 2000) during fusion.
Perhaps this chain is involved in maintaining conformation
or stabilizing the helical repeat, such that its complete re-
moval is lethal. However, removal of just the SA residue
from the terminus of this chain might enhance fusion.
Like the attachment proteins of many paramyxoviruses,
the G protein might express endogenous neuraminidase
activity or esterase activity, which would remove or destroy
some of the SA on the virion. In that case, exogenously
supplied neuraminidase might not have a noticeable effect
on fusion, unless the G protein is absent. The finding that
the fusion of rgRSV–GF-infected cells is enhanced by neur-
aminidase to a similar extent as rgRSV–F-infected cells
argues against this possibility. Furthermore, we were unable
to detect any neuraminidase or esterase activity associated
with the G protein in virions (N. Barretto and M.E. Peeples,
unpublished data).
In summary, we have shown that neuraminidase treat-
ment increases cell–cell fusion in virus-infected cells and
virus–cell fusion. This effect is due to the removal of sialic
acid residues from the effector cells or virus only. Removal
of the negatively charged sialic acid from these surfaces
may allow slightly more efficient binding to heparan sulfate
on the surface of target cells, perhaps by reducing electro-
static repulsion. However, better binding accounts for only
a portion of the increase in infectivity, suggesting that an-
other step, probably fusion, is also enhanced. Neuramini-
dase treatment also enabled us to detect fusion in cells
transiently expressing the F protein, with or without the G
protein. Before neuraminidase treatment, we had been un-
able to detect fusion in these cells. This finding should
facilitate the study of the fusogenic activity of F protein
mutants. Furthermore, the infectivity of RSV stock virus,
particularly viruses containing F as their only glycoprotein,
can be increased by treatment with neuraminidase. We have
also shown that spinoculation of cultured cells can be used
to dramatically increase the infectivity of RSV. Spinocula-
tion has been previously shown to increase the infectivity of
HIV-1 through the enhancement of binding (O’Doherty et
al., 2000).
In vivo, neuraminidases produced by viruses, bacteria,
and fungi, such as influenza and parainfluenza viruses,
Pseudomonas aeruginosa, Streptococcus, Pneumococcus,
Cryptococcus, and Pneumocystis carinii may affect the
course of RSV disease in coinfections of the respiratory
tract. Some of these organisms are opportunistic pathogens
in immunocompromised individuals. The neuraminidase
they produce could enhance RSV infection, spread, and
disease, which is known to be particularly severe in these
patients (Fishaut et al., 1980; Hertz et al., 1989; Krinzman
et al., 1998).
Materials and methods
Cells and viruses
HEp2, Vero, HeLa, and BHK-21 cells were obtained
from the American Type Culture Collection. HEp2 cells
were maintained in OptiMEM (Gibco, Invitrogen, Carlsbad,
CA) 2% fetal bovine serum (FBS). Vero cells were main-
tained in RPMI 1640 (Gibco), 5% FBS. HeLa and BHK-21
cells were maintained in DMEM (Gibco), 10% FBS. All
cells were incubated at 37°C, 5% CO2.
Virus was grown in HEp2 or HeLa cells and titrated on
the same cells. For titration, 10-fold dilutions of the virus
were made in OptiMEM, 2% FBS. Twenty microliters of
each dilution was added to cells in a 96-well plate. After
incubation for 1 h with rocking, inocula were removed and
replaced by OptiMEM, 2% FBS. Cells were incubated for
18–24 h at 37°C before observation. The number of green
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cells in each well was counted under an inverted focus
fluorescent microscope. Titers were calculated taking into
account dilution factors and volumes used for inoculation
and expressed in pfu/ml.
Construction and rescue of recombinant RSV expressing
all three viral glycoproteins (rgRSV–SGF) and the en-
hanced GFP was described previously (Hallak et al., 2000b)
Mutants of this virus lacking the gene for the SH protein
(rgRSV–GF) or lacking the genes for both the SH and the G
proteins (rgRSV-F) have been described (Techaarpornkul et
al., 2001).
Neuraminidase treatment
Viruses or cells were treated with neuraminidase from
Clostridium perfringens (Sigma Chemicals, St. Louis, MO)
diluted in serum-free OptiMEM in the presence of the
protease inhibitors leupeptin (0.5 g/ml), aprotinin (10 g/
ml), and PMSF (1 mM). Treatment was carried out at 37°C,
5% CO2, for 1 h. The sample was then diluted by the
addition of serum-containing medium to neutralize the neur-
aminidase before cells were inoculated.
Spinoculation
Virus was diluted in OptiMEM, 2% FBS, and 0.4 ml was
added to each well of a 12-well plate. Plates were spun at
1750g for 15 min at 4°C in a Sorvall RT6000B centrifuge
and transferred to 37°C, 5% CO2, for 30 min. The inoculum
was removed and replaced by OptiMEM, 2% FBS. Plates
were incubated at 37°C for 20 h. The cells were removed
from the plastic with trypsin and fixed, and the fluorescent
green cells were counted by flow cytometry.
Heparinase I treatment of cells
Cells were rinsed with PBS and incubated with 2 mIU/ml
heparinase I (Sigma Chemicals) diluted in OptiMEM, 2%
FBS, containing protease inhibitors at 18°C for 2 h. Hepa-
rinase was removed and the cells were rinsed three times
with PBS before addition of the inoculum.
Fusion assay
Cell–cell fusion was assayed as described (Nussbaum et al.,
1994), with minor modifications (Techaarpornkul et al., 2001).
Briefly, effector HeLa cells in a 48-well plate were inoculated
with rgRSV–GF or rgRSV–F, incubated for 24 h, and super-
infected at an m.o.i. of 5 with vT7lacOI, a recombinant vac-
cinia encoding T7 polymerase under the control of a lac-
inducible promoter (Alexander et al., 1992). One hour later the
medium was replaced with medium containing 0.1 mM iso-
propyl-1-thio--D-galactoside. Target HeLa cells were infected
with vCB21RlacZ (Alkhatib et al., 1996), a recombinant vac-
cinia encoding -galactosidase under the control of a T7 pro-
moter at an m.o.i of 5–10 and incubated for 18 h. To account
for non-fusion-related background, control effector cells were
infected with vT7lacOI alone. At 36 h after the initial RSV
infection, RSV-infected effector cells or control effector cells
were either treated with neuraminidase (70 mU/ml) or not.
Alternatively, the vCB21RlacZ-infected cells were treated
with neuraminidase or not. The vCB21RlacZ-infected target
cell population was removed from the surface of the dishes
using Versene (Invitrogen), rinsed once with OptiMEM, 2%
FBS, 250 mM CaCl2, and twice with OptiMEM, 2% FBS,
before being resuspended at 3 106 cells/ml. A total of 200l
of the target cells were then overlaid on the RSV-infected
effector cells. The populations were incubated together for 3 h
before being lysed by the addition of 5 l 10% NP-40. A total
of 50 l of the lysate was mixed with 50 l CRPG (chloro-
phenol-red--D-galactopyranoside; Boehringer Mannheim) 16
mM CRPG, 0.12 M Na2HPO4 · H2O, 0.08 M NaH2PO4 · H2O,
0.02 M KCl, 0.002 M MgSO4 · 7H2O, 0.01 M -mercapto-
ethanol) in a 96-well flat-bottom plate. After incubation at
20°C for 1 h, the intensity of the yellow color was determined
at 570 nm on a plate reader (Ceres UV 900 Hdi: Biotek
Instruments, Inc.). Control values were subtracted from exper-
imental values before plotting.
Binding assay
HeLa cells were inoculated with rgRSV–GF or
rgRSV–F. After 24 h, the medium was replaced with
DMEM lacking methionine and cysteine (Gibco), supple-
mented with 100 uCi/ml [35S]methionine and [35S]cysteine
(Trans 35S-Label, ICN). The virus was harvested after a
24-h labeling period. The virus was then purified twice by
ultracentrifugation through linear sucrose gradients (25 to
55%). Fractions of 1 ml were collected manually in the
region of 35–40% sucrose, and the cpm in each fraction was
counted. Fractions containing the highest cpm were pooled.
For the binding assay, 20,000 cpm/well of virus was
suspended in MEM (Gibco) and treated with 60 mU/ml
neuraminidase, or not, for 1 h at 37°C. Bovine serum albu-
min was added to a final concentration of 1% and the virus
was added to HeLa cells in a 24-well plate and incubated for
1 h at 4°C. The inoculum was then removed and the cells
were rinsed three times with cold PBS, lysed in 100 l
RIPA buffer, and analyzed in a scintillation counter (Beck-
man LS5000TD).
Velocity gradient sedimentation
Purified, 35S-labeled rgRSV–GF and rgRSV–F were pre-
pared as in the previous section. Virus was suspended in
MEM and treated with 60 mU/ml neuraminidase or mock
treated for 1 h at 37°C. The treated virus was then laid on
top of 15–45% linear sucrose gradients. The gradients were
centrifuged at 11,000 rpm for 10 min at 10°C using a SW27
rotor in an ultracentrifuge (Beckman). Fractions of 1.5 ml
were collected from the bottom of the tube using a fraction
collector (Gilson, Middleton, WI) and analyzed in a scin-
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tillation counter. The sucrose concentration of each fraction
was determined using a refractometer (Bausch and Lomb).
Plasmids
The F and G genes of RSV were PCR amplified from the
infectious cDNA clone and inserted into the NcoI and
BamHI sites of the vector pTM1 (Moss et al., 1990), down-
stream of the T7 promotor. The pTM1 plasmid encoding the
SH gene was HG122. The humanized Renilla green fluo-
rescent protein, R-GFP (Stratagene), was similarly cloned
into pTM1.
Fluorescence microscopic analysis of syncytium formation
HeLa cells were cotransfected with pTM1–GFP and
pTM1–F alone, or along with pTM1–G and pTM1–SH,
using HeLa Monster reagent (Mirus, Panvera, Madison,
WI). The cells were infected with recombinant vaccinia
virus, vTF7–3 (Fuerst et al., 1987). After 48 h, the cells
were either treated with 200 mU/ml neuraminidase, or not,
for 45 min at 37°C. The cells were then viewed under an
inverted fluorescence microscope (Nikon Optiphot) and
photographed with a digital camera (Roper Scientific).
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